Helicobacter pylori (H. pylori) is widely recognized as the most common chronic bacterial infection on the planet, affecting over half of the global population [1, 3]. Typically acquired during childhood, this bacterium persists for life unless specifically treated [1]. It resides in the stomach lining and is the primary cause of chronic gastritis, persistent dyspepsia, and peptic ulcer disease [1, 8]. Furthermore, long-term infection is a major risk factor for the development of precancerous gastric conditions, such as atrophic gastritis, and stands as the leading cause of infection-attributable gastric cancer worldwide [3, 8]. Because of these serious health risks, international guidelines strongly advocate for the detection and eradication of H. pylori in all infected individuals to reduce gastric cancer-related deaths [3].
Diagnostic Approaches For Stomach Bacteria
Detecting H. pylori can be accomplished through both invasive and non-invasive methods depending on clinical presentation [1]. For young patients experiencing dyspepsia without any alarm symptoms, a preferred approach is the test-and-treat strategy, which relies on non-invasive testing followed by targeted therapy [1]. Common non-invasive options include the carbon-13 (${}^{13} ext{C}$) urea breath test and stool antigen tests [1, 6]. Conversely, invasive diagnosis typically requires an upper endoscopy, allowing clinicians to perform a rapid urease test or obtain histological tissue samples [1]. Advanced molecular methods are also emerging to detect the bacterium and evaluate antibiotic sensitivities directly from gastric samples [4].
Standard Eradication Regimens And Challenges
Treating H. pylori generally involves a combination of acid-suppressing medications, such as proton pump inhibitors (PPIs) or newer agents like vonoprazan, paired with specific mixtures of antibiotics or bismuth salts [1, 4]. However, managing the infection has grown increasingly challenging due to rising global antibiotic resistance [2, 3]. Resistance to standard agents like clarithromycin frequently exceeds 15% to 20% in many regions, significantly reducing the effectiveness of conventional first-line treatments [7]. Consequently, healthcare providers increasingly utilize molecular diagnostic tools or tailored sensitivity testing to choose optimal alternative regimens, such as second-line quadruple therapies [4, 6].
Confirming Treatment Success
Because antibiotic resistance can cause initial treatments to fail, confirming the complete eradication of H. pylori post-therapy is a critical step in clinical management [5, 6]. Standard follow-up evaluations—such as the urea breath test—are recommended weeks after finishing medication to verify that the bacteria have been successfully cleared [6]. Ensuring eradication helps prevent the recurrence of peptic ulcers and lowers the long-term risk of severe gastric complications [3, 5].
Sources
- 1. [Helicobacter pylori and gastric disease]. Medicina clinica, 2025.
- 2. A Quality Improvement Initiative to Increase Helicobacter pylori Testing and Eradication Among Patients Diagnosed With Peptic Ulcer Disease in a U.S. Safety-Net Hospital. Journal of clinical gastroenterology, 2026.
- 3. Diagnosis and treatment of <i>Helicobacter pylori</i> infection: past, present, and future. Future microbiology, 2025.
- 4. Clinical practice of a novel molecular diagnostic method for detecting Helicobacter pylori and clarithromycin resistance. Fukushima journal of medical science, 2025.
- 5. Helicobacter pylori-associated peptic ulcer disease: A retrospective analysis of post-treatment testing practices. Helicobacter, 2018.
- 6. Confirmation of Helicobacter pylori eradication using ¹³C urea breath test: addressing the regional post-treatment outcomes. BMC gastroenterology, 2025.
- 7. <i>Helicobacter pylori</i> eradication: a narrative review. Frontiers in gastroenterology, 2026.
- 8. The importance of <i>Helicobacter pylori</i> eradication: a narrative review. Frontiers in gastroenterology, 2026.